TYRA-300

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

9mo

TYRAPhase 2$1.8B

TYRA-300 Phase 2 Results Expected

TYRA-300• Locally Advanced Urothelial Carcinoma310

Nov 15Estimated

00%

Competitive Landscape

0 competitors in Locally Advanced Urothelial Carcinoma

Drug Information

Target Indication

Locally Advanced Urothelial Carcinoma

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

TYRA

Tyra Biosciences, Inc.

Related Pipeline

Low-grade NMIBC

Achondroplasia

Low Grade Upper Tract Urothelial Carcinoma